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ABSTRACT 
The most common type of birth defects are congenital heart defects (or CHDs). Though a 
few cases of CHDs have been attributed to genetic defects specific to the heart, substance 
exposure, or to maternal disease, the cause of most CHDs is unknown. Thus, further 
research is needed to determine how CHDs form. Very few studies have investigated how 
physiological factors like perturbations of blood flow can affect normal heart 
development. For instance, increasing or decreasing the resistance to blood flow can alter 
development of the heart in both zebrafish and chicken embryos. This could be one 
mechanism to explain CHD formation, but further investigation in a mammalian system 
is needed. To examine this idea, I experimentally manipulated cultured mouse embryos, 
testing the effects of decreased blood viscosity (to create low hemodynamic force 
[cardiovascular system] or low hemodynamic loading [heart-specific]). To determine the 
effects on heart development, I prepared the embryos for 3D imaging by optical 
projection tomography (OPT), and assessed heart volume and myocardial thickness. 
There was no detectable change in the volume of hearts under low hemodynamic force 
compared to hearts with normal hemodynamic force. However, I did observe a decrease 
of myocardial thickness in hearts with low hemodynamic force compared to control 
hearts. Thus, this study demonstrates that even at very early stages of embryonic 
development, alterations in blood flow can influence heart development. This indicates 
CHD formation can be exacerbated upon initial exposure to a primary cause (genetic 
defects, substance exposure or maternal disease) due to changes in hemodynamic forces. 
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 1 
INTRODUCTION 
 
The Cardiovascular System 
          The cardiovascular system is comprised of the heart and blood vessels that function 
to pump and distribute blood (for oxygenation) and plasma (containing nutrients, waste 
products, and other molecules) throughout the rest of the body. At the core of the 
cardiovascular system is the heart. In mammals, the heart is a four-chambered structure, 
composed of right and left atria, which pump blood into ventricles, and the right and left 
ventricles, which pump blood into the lungs and rest of the body. Blood exits the heart 
and into the rest of the body via the circulatory system which is comprised of an 
interconnected, branched system of arteries that feed into tiny capillaries, and finally 
these become collected back into veins that bring blood back to the heart (Udan et al., 
2013).  
          The heart is a very critical structure for survival of vertebrate organisms because 
without its function, the organism would be deprived of oxygen and nutrients 
(Buckingham et al., 2005). Proper functioning of the adult heart relies upon a 
coordination of contraction between atria and ventricles, the proper presence of septa, and 
valves, all of which allow for the forward movement of blood (van Weerd and 
Christoffels, 2016).   
          There are many ways in which the heart can fail to function (heart failure or HF). 
The most common cause of defective heart function is a myocardial infarction (MI, 
commonly known as a heart attack). MIs occur when blood flow to the heart via the 
coronary arteries is cut off (Keeley et al., 2003). This results in death of the myocardium 
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and can be lethal (Daubert and Jeremias, 2010). Though myocardial infarction is a 
product of atherosclerosis (vascular disease), this usually occurs in adulthood due to a 
complex mixture of environmental and other risk factors. Defective heart function does 
not exclusively occur in adulthood. Many functional issues are caused by defects 
resulting from improper development of the heart that occurs during embryogenesis and 
fetal development.  
 
Congenital Heart Defects 
Birth defects impacting the morphology and function of the heart are the most 
common and lethal type of birth defects (Jenkins et al., 2007). These defects are called 
congenital heart defects (CHDs). Some CHDs go unnoticed or have such minimal effects 
on the organ’s function that treatment is not needed, whereas others require treatment 
soon after birth (Bull, 1999).  
Though CHDs occur in about 1 out of 100 births, the ratio would be higher if it 
included embryos with CHDs (Hoffman, 1995). This can be explained by the fact that 
defects in embryonic heart development can result in spontaneous abortions 
(miscarriages), particularly in the first trimester, and thus they would never be reported as 
having a CHD (Bruneau, 2008; Goldstein, 1994; Makikallio et al., 2005).  
There are many known causes for CHDs. These causes can be categorized into 
three groups: maternal disease, substance exposures, and genetic causes. First, maternal 
health is crucial for the proper development of offspring. Unfortunately, there are many 
diseases and conditions a mother can have that may negatively impact a developing 
embryo. One study on women with phenylketonuria found those who do not regulate 
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their diet have >12% chance of having a child born with a CHD (Rouse and Azen, 2004). 
Mothers with unmanaged diabetes have 3-5 times the risk of having offspring with a 
CHD (Nassr et al., 2016) than healthy mothers. Maternal epilepsy is associated with 
CHDs. However, it has been difficult to parse apart the effects of the condition versus the 
effects of treatments for epilepsy. Many of the treatments for epilepsy disrupt the 
metabolism of folate, a necessary component of the maternal diet. Lastly, infections 
during pregnancy such as Influenza (and many other disease accompanied by a persistent 
fever) are also associated with an increased risk of CHDs (Jenkins et al., 2007; Oster et 
al., 2011). 
Another way CHDs have been induced is through exposure of the mother to 
teratogenic substances and/or lack of nutrients needed in her diet. Teratogens, such as 
thalidomide, are known to cause congenital deformities including phocomelia (limb 
deformities (Vargesson, 2009)) and of course, CHDs (Smithells and Newman, 1992). 
Some studies have found an association between cigarette smoking and CHDs, but these 
findings have not been supported by larger studies. Alcohol, on the other hand, has been 
associated with many congenital deformities including CHDs. Some retinoids (aside from 
vitamin A) have associations with CHDs. Particularly, the drug Isotretinoin, which was 
previously prescribed for severe acne, is associated with CHDs as well as abnormalities 
in other organs including the thymus and eyes. There is an association between women 
who report working with organic solvents as part of their occupation and having children 
with CHDs, particularly ventricular septal defects (VSDs). One large registry study found 
that the use of nonsteroidal anti-inflammatory drugs has an association with CHDs 
(Ericson and Kallen, 2001). If the mother contracts Rubella during pregnancy, it can 
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spread to the fetus and cause CHDs and other developmental defects. Supplementation 
with folic acid is important for both proper neural tube closure and cardiac formation 
(Jenkins et al., 2007).   
Lastly, some CHDs have been found to have genetic origins. Children with a 
chromosomal abnormality (such as trisomy 21 or trisomy 18, 22q11.2 deletion, and 
trisomy 13) have an increased risk of CHDs (Hartman et al., 2011). However, identifying 
the specific genes that, upon their deletion or duplication, cause the CHD in these 
syndromes can be problematic because a multitude of genes are misregulated in 
chromosomal abnormalities. On the other hand, there are many single genes involved in 
the development of the heart that have mutations known to cause CHDs. These mutations 
directly impact the heart or the vasculature of a developing embryo and will be discussed 
later. 
It is clear from previous studies that improper formation of the heart occurs 
through a complex interplay of environmental and genetic causes. While these causes are 
known to affect heart development, a significant portion of CHDs have no detectable 
cause (Patel and Burns, 2013). Thus, more studies need to be done to reveal how CHDs 
arise. Insight in this area can be provided by understanding how normal heart 
development occurs. 
 
Vertebrate heart development 
The vertebrate heart is essential for the delivery of oxygen and nutrients as well as 
movement of metabolic waste products out of tissues. In very early stages, embryonic 
tissues are thin enough for this process to occur via diffusion. However, as the embryo 
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grows, simple diffusion is not sufficient. As such, the heart becomes the first functioning 
organ in the embryo to facilitate the distribution of these substances (Udan et al., 2013). 
In mice, heart development begins with the specification of heart cell 
precursors—a tissue called the cardiogenic mesoderm—that forms from the medial 
lateral-plate mesoderm at embryonic day E6.5 (6.5 days after fertilization) (Saga et al., 
1999). The cardiogenic mesoderm (or the heart field) of vertebrates forms during 
gastrulation (before lateral-plate mesoderm forms). Eventually, these cells reach the 
inside of the embryo in a location close to the pharyngeal arch, where they become 
specified into two separate fates: first heart field and second heart field. Cells of the first 
heart field leave the lateral-plate mesoderm (on both the left and right sides of the body) 
and these cells undergo mesenchymal to epithelial transformation on either side of the 
midline forming two heart tubes. Next, cells of the second heart field incorporate into the 
tubes, and the tubes fuse together at the midline to create a structure called the heart tube. 
The heart tube at this point is comprised of an inner lining of endocardial cells 
surrounded with contractile cells called cardiomyocytes (Buckingham et al., 2005). 
Cardiomyocytes make up the myocardium of the heart, and these are identifiable by the 
appearance of smooth muscle α-actin expression (Clement et al., 2007; Potta et al., 2010).  
The incorporation of second heart field cells into the initial heart tubes is not uniform, as 
the first heart field primarily gives rise to the left ventricle, and the second heart field 
primarily gives rise to the right ventricle, left and right atria and the outflow tract (OFT) 
(Rochais et al., 2009).  
After the heart tube forms, the heart undergoes morphogenesis to eventually form 
a four-chambered heart. This initiates around E8-9 in mice and between days 20-28 of 
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human gestation by undergoing looping. Nodal and Pitx2 are proteins that pattern the left 
and right sides of the embryo. These proteins control which direction the heart will loop 
by acting as transcription factors regulating the expression of genes associated with the 
cytoskeleton (e.g. actin) (Noel et al., 2013). Prior to looping, both Hand1 and Hand2 are 
located throughout the heart tube pericardium. These proteins are controlled by Nkx2-5. 
Once the heart starts looping, Hand1 is exclusively expressed in the left ventricle, and 
Hand2 is expressed on the right side of the heart. The ventricles of the heart do not form 
as they should if any of these proteins are missing. Thus, looping is also impeded without 
these proteins (Biben and Harvey, 1997; Buckingham et al., 2005; Srivastava et al., 1995; 
Srivastava and Olson, 2000). 
Other features of the heart formed during embryonic organogenesis include 
trabecula and septations, which help form the four chambers of the heart. Trabecula, 
found in the ventricles, are projections of the myocardium that form a mesh-like matrix 
on the inside of the heart. They start forming around E9.5 in mice (Captur et al., 2016). 
These formations are important for cardiac function as they help with strengthening and 
septating the ventricles, as well as acting as a precursor to the Purkinje fiber network of 
the cardiac conduction system (Granados-Riveron and Brook, 2012; Haack and 
Abdelilah-Seyfried, 2016; Niessen and Karsan, 2008; van Weerd and Christoffels, 2016).   
Septations of the heart can be both thick and muscular as found between the left 
and right ventricles or membranous as occurs between the left and right atria. The 
ventricular septum begins to form around E11 in mice and starts on the inferior groove 
between the right and left ventricles. An equal portion of cells from both chambers 
proliferate upwards, creating the full septation by E12.5 (Christoffels et al., 2000; 
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Harvey, 2002). Unlike the ventricles, the atria of the mammalian heart are not fully 
separated until birth. This occurs due to a change in pressure when the first breath is 
taken. During development, the septum primum and the septum secundum form to 
partially form between the left and right atrium. They are not completely connected, but 
have a space called the foramen ovale to direct the flow of blood that is partially 
oxygenated from the placenta from the right atrium to the left atrium until birth. 
(Dalgleish, 1976; Kijima et al., 2017).  
Lastly, the valves of the heart found at the outflow tract and at the atrial-
ventricular junctions are needed to prevent backflow of blood. The valves are derived 
from endocardial tissue, specifically structures called the endocardial cushions. The 
endocardial cushions are made of an extracellular matrix called the cardiac jelly, which 
contains endothelial cells that undergo endothelial to mesenchyme transdifferentiation 
(EMT). These cells proliferate and migrate to form the valves. Signals identified in this 
process include (VEGF) for proliferation; NFATc1 in the endocardial cushions as a 
transcriptional regulator; Notch, Wnt/β-Catenin, and BMP/TGF-β for EMT;  ErbB seems 
to regulate proliferation of the cells making up the valves; and NF1/Ras function to 
control EMT (Armstrong and Bischoff, 2004). 
For each aspect of heart morphogenesis (looping, trabeculation, septation, 
chamber formation, and valve formation), a complex interplay of signals must be 
involved. To elucidate genetic signals, mutations in various genes have revealed 
impairment of proper heart morphogenesis leading to a CHD. These studies thus reveal 
critical genes that are involved in proper heart formation.  
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Genetically Generated Congenital Heart Defects  
Many cases of CHDs in humans are linked to mutations in genes that are directly 
involved with heart development. Among these are NKX2.5, GATA4, TBX5, TBX20, 
SALL4, ZIC3, TFAP2B, FOG2, and TBX1 (Clark et al., 2006; Garg et al., 2003). These 
genes are all transcription factors that regulate heart development. Some of these genes 
work together to either activate or repress certain genes, like TBX5 and SALL4. As a 
result of this overlapping, the patterns of gene expression controlling heart development 
are quite complex (Bruneau, 2008).  
To determine whether mutations in these genes are causative of CHD formation, 
researchers rely on information gleaned from model organisms. Mutation in many of the 
aforementioned genes in mice, for example, result in CHD formation. Mice that are 
homozygous mutant for Nkx2.5 mice exhibit arrest of cardiac development after looping 
(Tanaka et al., 1999). Also, Gata4 knockout mice reveal CHDs characterized by impaired 
looping, septation, and a hypoplastic ventricle (Watt et al., 2004). Thus, there are clearly 
specific mutations in genes that directly cause CHD formation; however, this is only part 
of the story. 
In addition to mutations in genes that control heart development, CHD formation 
has been linked to mutations in genes that are required for cardiac contractility. There are 
various examples of these genes across different species. In humans, α-Cardiac actin 
(ACTC1), α-Cardiac myosin heavy chain (MYH6), and α-Cardiac myosin heavy chain 
(MYH7) are mutations that have been linked to CHDs (Granados-Riveron and Brook, 
2012). Mutation of cardiac contraction genes also give rise to CHDs in zebrafish (cardiac 
troponin T [tnnt2], sarcomeric actin [cfk], and atrial myosin heavy chain [amhc], 
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(Bartman et al., 2004; Berdougo et al., 2003)), chickens (atrial myosin heavy chain 
[MYH7] (Rutland et al., 2009)), and mice (Myosin light chain 7 (Myl7) (also known as 
Myosin light chain 2a [Mlc2a]), Cardiac troponin T (Tnnt2), and Na2-Ca2 exchanger 
(Ncx1) (Anderson et al., 2015; Cho et al., 2000; Huang et al., 2003; Nishii et al., 2008). 
These mutations lead to a complex pathogenesis that is difficult to elucidate because in 
addition to affecting cardiac contractility directly, they also affect hemodynamic forces of 
blood flow, which may also be required for normal heart development (see below). 
There are several pieces of evidence that implicate hemodynamic force in normal 
heart development. For example, there are also many genes involved in sensing sheer 
stress or acting in cell to cell communication that cause CHDs. Also, mutations that affect 
blood vessel development directly can be comorbid with impaired heart development. For 
example, vascular-specific alterations in Notch signaling (using Tie2-Cre) in the mouse is 
known to impair vascular development. For instance, vascular loss of Notch1 results in a 
failure for vessels to remodel (Limbourg et al., 2005), and activation of Notch1, via 
overexpression of Notch1-intracelullar domain (N1ICD), results in the presence of large 
sinusoidal vessels that also do not remodel (Copeland et al., 2011). In these same studies, 
vascular Notch1 inactivation also resulted in hearts with a thin myocardial wall and 
delayed looping; whereas, hyperactivation of Notch1 resulted in enlarged hearts. One 
interpretation of the observed heart defects is that the improperly remodeled blood 
vessels lead to an increase in resistance of blood flow, and as a result, the impaired blood 
flow may cause a secondary defect in heart development. The major caveat to 
interpreting these studies in this way is that the Tie2-Cre transgene is also expressed in 
the inner lining of the heart (the endocardium). Thus, these studies do not reveal if altered 
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Notch activity affects heart development directly or indirectly, and more studies should 
be done to elucidate the effect of altered flow dynamics on heart development.  
 
CHDs generated by mechanical changes in hemodynamics 
Various mechanical studies in fish and bird models implicate that alterations in 
hemodynamic force can affect heart development. A study in zebrafish manipulated 
hemodynamic force of 37 hours post fertilization (h.p.f.) embryos by inserting glass 
beads in the inflow and outflow tracts of the developing hear tube (Hove et al., 2003).  
This study found that by 4.5 days post fertilization (d.p.f.), obstructed blood flow at both 
the inflow and outflow tracts prevented looping and proper formation of the ventricle and 
atrium. There have been many studies that manipulate the hemodynamic loading of the 
chick embryonic heart (Midgett and Rugonyi, 2014). One way this has been 
accomplished is via ligation of the vitelline vein, the vein that returns blood to the chick 
heart. In one such study, a microclip was added to the right lateral vitelline vein of a stage 
17 (70 hour incubated) chicken embryo in ovo and then incubated until stage 24 or 34 
(26-122 hours). The 24 stage embryos exhibited looping defects and some hypoplasia of 
the endocardial cushions (Broekhuizen et al., 1999). Many of the embryos incubated to 
stage 34 had ventricular septal defects and semilunar valve defects.  Another study 
induced a hypoplastic left heart (HLH) in chicken embryos by ligating the left atrium 
(deAlmeida et al., 2007). They found it was possible to rescue the HLH chicks by also 
ligating the right atria to increase the loading in the left ventricle.  
There has been little done to assess the effect of mechanical manipulations of 
hemodynamic force on embryonic mouse hearts. This is due to the challenges of 
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culturing mouse embryos ex vivo along with the difficulty of manipulating these 
embryos. Mechanical studies conducted thus far have mainly examined the impact on 
vasculature and not the heart. One study assessed how ligating the left sixth branchial 
arch artery of an E11-11.5 mouse embryo compares to the right, non-ligated sixth 
branchial arch artery after culturing for 36 hours. They noted there was regression in the 
left sixth branchial arch artery compared to the right (Yashiro et al., 2007). Another study 
found that hemodynamic forces influence the development of the vasculature of the yolk 
sac in mice (Lucitti et al., 2007).  In that study, the hematocrit was reduced in 5 somite 
stage mouse embryos by retaining blood cells in the yolk sac (the initial site of 
erythrocyte generation) with polyacrylamide and cultured for 24 hours. This lowered the 
hemodynamic force in a way that prevented remodeling of the yolk sac vessels. By 
administering hetastarch, which acts as a blood thickener, increasing hemodynamic force, 
to reduced hematocrit embryos prior to culturing, remodeling of the yolk sac vessels was 
rescued. This also revealed that remodeling failure upon reduction of hematocrit was not 
caused by improper oxygenation, as the rescue experiment does not provide back extra 
oxygenation. 
 
Hypothesis 
Taken together, these studies in zebrafish and chicken embryos have implicated 
that hemodynamic force is a factor that controls heart development. The role of 
hemodynamic force is not limited to avia or teleosts, as mouse embryonic vessels are also 
regulated by force. Thus, I have hypothesized hemodynamic force plays a role in mouse 
embryonic heart development. I studied this by applying the same mouse embryo culture 
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and hemodynamic force manipulation methods as described in (Lucitti et al., 2007). The 
focus for this study was on what happens to mouse embryonic heart development when 
hemodynamic force is reduced via retaining the blood cells in the blood islands of the 
yolk sac.   
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METHODS 
 
Experimental design 
Because mammalian embryos develop in utero, this limits accessibility of 
embryos for a whole host of experiments, including visualizing development, performing 
transplantation or extirpation studies, fate mapping, or other ways of manipulating 
embryos. To perform these experiments, the embryos must be removed from the uterus 
and cultured externally. Both preimplantation and post implantation embryos (up to 
E10.5) can be cultured externally for up to 24 hours (sometimes longer), though different 
culturing approaches (media, gaseous phases, or removal of yolk sac) may be needed 
depending on what stage the embryos are extracted from the mother. In this study, 
embryos were removed at E8.5, and cultured using techniques highlighted below.   
 
Procedures 
Mouse line and maintenance. CD1 mice with an Myl7 null mutation were 
maintained according to Institutional Animal Care and Use Committee (IACUC) 
protocols established by Missouri State University (November 20, 2014; approval #15-
004.0-A, December 01, 2014; approval #15-008.0-A). For embryo manipulation studies, 
only CD1 mice that were homozygous for the wild type allele of Myl7 were used. 
Breeding mice in this way ensures that I efficiently uses this mouse line (as per IACUC 
rules) while retaining the Myl7 mutation for other experiments (such as for the 
developmental delay experiment). Animals were housed according to the guidelines set 
by the National Institutes of Health (NIH).  The mice were kept in a room at ambient 
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temperature (23-26 °C) on a 12 hour day/night cycle starting at 7 A.M. All adult mice 
were maintained on a diet of Purina Labdiet 5001 in a clean standard shoebox cage 
(Ancare) with ad libitum access to food and water. However, if the mice were used for 
breading or experiments, they were fed Purina Formulab diet 5008.  
For embryo manipulation studies, Myl7+/+ (CD1 background) male and female 
mice were crossed, and the female was checked every morning for a vaginal plug. The 
day a plug was present was considered embryonic day 0.5 (or E0.5). The dissection of 
these embryos was done on E8.5.  
Mouse genotyping. To verify the genotype of the animals used, tissue samples 
for genotyping were collected from tail tips of recently weaned and tattooed mice, or 
from embryos. If adult mice needed to be genotyped, they were anesthetized with 3 ppm 
isoflurane before collecting a tissue sample from the tail. 
Tail cuts from weaned or adult mice were digested in 200 µl of tail buffer (TLB, 
0.1M NaCl, 0.05M Tris [pH 8.0], 0.1M EDTA [pH 8.0], 5 ml 10% SDS, q.s. to 50 ml) 
and 10 µl Proteinase K (Thermoscientific, #EO0491, Lot 00323614) overnight at 55 °C. 
The next day, DNA was extracted by adding 200 µl of phenol chloroform (Fisher 
Scientific, BP1753I-100), mixing by inversion, followed by centrifugation at 17.0 Xg for 
10 minutes. The upper phase (180 µl), containing the DNA, was removed and placed in a 
clean microcentrifuge tube. Isopropanol (180 µl) (Fisher Scientific, Cat. A461-500) was 
added to precipitate the DNA. The DNA was pelleted via centrifugation and the 
isopropanol was removed. A wash of 500 µl of 70% ethanol (Fisher BioReagents™, Cat. 
BP28184) was added and the tube was centrifuged again. Next, the ethanol was removed 
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and allowed to evaporate. The DNA was then suspended in 75 µl of distilled water and 
stored at 4 °C until needed for polymerase chain reaction (PCR).  
For the PCR, each reaction had 39 µl of master mix (15 µl distilled water, 2 µl of 
forward primer, 2 ul of reverse primer, and 20 µl Taq Pro Red Complete [Denville 
Scientific Inc., Lot BMR15-616110]) and 1 µl of DNA. Adult mice can only be 
homozygous wild type for the Myl7 gene, or heterozygous because Myl7-/- homozygous 
mutants are embryonic lethal by E10.5-E11.0. Thus, genotypes for adult mice were 
determined by detecting the null mutation by PCR. Specifically, the null mutation would 
be present if a 763bp PCR fragment forms using the following primers: Myl7 Mut-F 
(DNA sequence: 5′- ACAGGGAATCACA-3′), 2 µl Myl7 Mut-R (DNA sequence: 5′-
CGAACCTGGTCGA-3′). For genotyping embryos, presence of the mutation was 
detected, as previously mentioned, and presence of the wild type Myl7 allele was detected 
using Myl7 Wt-F (DNA Sequence: 5′-GGCACGATCACTC-3′), and Myl7 Wt-R (DNA 
sequence: 5′-ATCCCTGTTCTGG-3′) primers. The expected band for presence of the 
wild type allele is a 590bp fragment. The PCR was done with a TECHNE, 
3PRIMEBASE/02 using the following parameters: 95 °C for 5 minutes, 35 cycles (95 °C 
30 seconds, 56.5 °C for 30 seconds, 72 °C for 1 minute), 72 °C for 5 minutes, and 4 °C. 
Samples were run on an electrophoresis gel (2% agarose, with 12 µl ethidium bromide) 
with a DNA ladder (MidSci, Bulls eye, lot200217). The gel was imaged with a Gel 
Imaging System (Azure Biosystems, c300) and presence of the Myl7 mutation was 
assessed.  
Rat serum collection. Sprague-Dawley rats (about 7 weeks old, initially from 
Charles River, but bred in house) were anesthetized with diethyl ether (Acros Organics, 
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Cat. 123990010) in a desiccator (Fisher: 08 615B). Unresponsive rats were removed from 
the chamber and placed in supine position, and tested for adequate depth of anesthesia by 
assessing pedal withdrawal and palpebral reflexes. The nose and mouth were covered 
with a 50 ml Falcon tube containing an ether-soaked Kimwipe (Kimberly Clark Science 
brand) to ensure anesthetization during the procedure. The peritoneal cavity was opened, 
the organs were moved aside, and the viscera was moved away to expose the dorsal aorta. 
A BD Vacutainer® Safety-Lok™ Blood Collection Set (BD Medical Supplies, Ref 
367283) needle was inserted into the dorsal aorta and blood was drained into a BD 
Vacutainer SST™ Plus Blood Collection Tube (BD Medical Supplies, Ref 367985) that 
was inverted to mix in the anticoagulants. Euthanasia was completed by decapitation with 
a guillotine (Braintree scientific: NS-80-2).  
The blood collection tubes were then centrifuged at 13.0 xg for 20 minutes to 
purify the serum. All serum was then sorted into 15 ml Falcon tubes (MidSci, C15R) 
based on purity. High quality serum was labeled “clear”, followed by “medium”, and 
lastly serum containing a high proportion of lysed red blood cells labeled “pink”. These 
tubes were then centrifuged at 1300 RCF for 10 minutes to pellet any remaining blood 
cells. The serum was then decanted into three 50 ml Falcon tubes (MidSci, Cat. C50R, 
labeled “clear”, “medium”, and “pink”). These tubes were covered with a Kimwipe and 
placed in a 56 °C water bath for 30 minutes to heat inactivate the serum and allow the 
ether to evaporate. The tubes were then moved to 4 °C overnight to further evaporate the 
ether.  
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The next day, all serum was sterile filtered (Fisher Brand, Cat. No 09-719D) and 
1 ml of serum was aliquoted to 1.5 ml centrifuge tubes labeled with the date and quality. 
These were then stored at -80 °C for up to a year.  
Embryo culture. The night before dissection, two 1 ml aliquots of clear rat serum 
were removed from storage at -80 °C to allow dissipation of ether from the serum. Each 
of these tubes were opened, placed in loosely capped 50 ml Falcon tubes, and stored at 4 
°C until the next day.  
On the day of the dissection, dissection media containing 25ml of Dulbecco’s 
Modified Eagle Medium (Gibco® by Life Technologies™, REF 11330-032) 
supplemented with 5 ml fetal bovine serum (Gibco) and 0.5 µl of penicillin/streptomycin 
(Sigma, P4458-100ML) was made in sterile conditions.   
The loosely capped rat serum and dissection media tubes were placed in an 
incubator (Fisher Scientific™ Isotemp™ CO2 Incubator, Cat. 13-255-27) maintained at 
37 °C with 5% CO2 (Airgas, Randor, PA). About 1-2 ml of dissection media was placed 
in two 60 mm x 15 mm petri dishes (Fisherbrand™, Cat. FB0875713A) and eight 35 mm 
x 10 mm petri dishes (Falcon®, REF 351008). Everything was left in the incubator for at 
least an hour before the dissection.   
After the dissection and manipulation(s), embryos were allowed to equilibrate for 
an hour. During this time, two aliquots of culture media (1:11 ml rat serum to dissection 
media) were made in 50 ml Falcon tubes and gassed (Airgas, bloodgas mixture) for 3 
minutes to remove any remaining ether from the rat serum, and to balance the gaseous 
phase of the culture media. The culture media was emptied into 60 mm x 15 mm petri 
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dishes and allowed to equilibrate in the incubator for 1 hour. Embryos were then 
transferred into the respective plates and kept there for 24 hours.   
Dissection. Mice 8.5 days into pregnancy were sacrificed with CO2 and cervical 
dislocation. The peritoneal cavity was opened and one at a time, the uterine horns were 
removed. Incisions were made in the myometrium between each embryo to reduce 
tension of the contractions before moving to dissection media. The uterine horn was then 
placed in a 60 mm x 15 mm petri dish with dissection media (previously described). This 
dish was moved to the stage of a dissection microscope (AmScope, SM-1TSZ-L6W) 
surrounded by a homemade heater box (cardboard box with front cut out and covered in 
insulating material attached to a heater that maintains the temperature at 37 °C).  
Next, the embryos were completely cut apart and the myometrium was removed. 
Embryos were then moved to 35 mm x 15 mm culture dishes (no more than 4 per dish) 
filled with dissection medium and placed in the incubator. The decidua and parietal yolk 
sacs were carefully removed from one petri dish of embryos at a time, while keeping the 
visceral yolk sac and ectoplacental cone intact. These embryos were then transferred to a 
new 35 mm x10 mm culture dish with dissection media and stored in the incubator and 
the rest of the embryos were dissected.  
Microinjections. In Lucitti et al., 2007, a low hemodynamic force embryonic 
mouse model was created by preventing blood cells from leaving the blood islands; 
hence, these embryos were referred to as “reduced-hematocrit” embryos. By reducing 
hematocrit, this diminishes the amount of hemodynamic force that is normally provided 
by the high viscosity that blood cells create in flowing blood. In my thesis study, 
reduced-hematocrit embryos will be referred to as “low-hemodynamic loading” embryos 
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because it also has an effect of minimizing the amount of hemodynamic force that the 
heart is exposed to, as well as the amount of effort that the heart exerts in pumping blood. 
To make low-hemodynamic loading embryos, the yolk sac blood islands (where 
the pre-circulatory blood cells reside) must be injected with substances that prevent their 
entry into circulation. The substances used were Acrylamide (450 µl 2x PBS, 250 µl of 
DiH2O, 250 µl 30% Bis-acrylamide [Fisher Scientific, Cat. No. BP1366]), 50 µl India ink 
[American MasterTech, REF STIIN25], 20 µl 0.5 M ammonium persulfate [Thermo 
Scientific, CAS: 7727-54-0]) and TEMED (50 µl TEMED [Fisher BioReagents, CAS 
110-18-9], 50 µl 2x PBS, 2 µl India ink). The acrylamide and TEMED solutions were 
centrifuged at 17.0 xg for 1 minute and then sterile filtered to avoid clogging the very 
thin microinjection needle. The experimental embryos were injected with both 
acrylamide and TEMED (AT) into the blood islands resulting in low hemodynamic 
loading embryos (because blood cells failed to enter circulation). For one category of 
control embryos, only the solution of acrylamide (Ao) was injected into the blood islands, 
and blood cells still entered circulation. For N control embryos, no injections were 
performed and these embryos were transferred to culture media at the same time as the 
AT and Ao embryos (Fig. 1).  
In embryos 8 somites and younger, the flow of blood in the yolk sac blood islands 
is so low that the acrylamide, TEMED, and blood cells remain in these areas once 
polymerized. However, after 8 somites the blood cells begin to enter circulation. Thus, 
embryos used for injections were between 4 and 6 somites. 
Acrylamide injections were done in the proximal yolk sac blood islands 2 to 3 
times in 3 to 4 sites of the blood islands. After the acrylamide injections, the embryos 
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were replaced in the incubator to equilibrate for 15 minutes. Then (for AT embryos), a 
similar amount of TEMED was injected at the same injection sites as the acrylamide. 
Embryos were then transferred to culture media to culture for 24 hours.    
Needles used for injection were made using 0.4 mm I.D. length 75 mm capillary 
tubes (Drummond Scientific Co., Cat. # 1-000-800) pulled on a PMP-102 Micropipette 
Puller (MicroData Instrument, Inc., PMP-102) set on the preprogrammed sequence SQ20 
for a taper length of 3 mm, an outer diameter of 2-20 µm, and a tip opening of <1-2 µm.  
Injections into the proximal yolk sac blood islands were performed with a Pico-
Liter Injector (Warner Instruments, PLI-10) set at 3 PSI With an injection time of 0.10 
seconds.   
Heart staining and OPT processing. After culturing for 24 hours, viability of 
the embryos was determined. Though most control embryos used for this study were with 
injections with acrylamide alone, TEMED only injections have been tested before, and 
these did not appear to have any difference in health of the embryos similar to acrylamide 
injections. Health of the embryo was determined by assessing several factors: 1) 
continued cardiac contraction and blood flow; 2) remodeling of the yolk sac vasculature; 
3) analysis of extent of embryogenesis (i.e., the embryo undergoes turning, 
somitogenesis, growth, etc.). Thus, controls exhibited healthy heart contractility, blood 
flow, vascular remodeling, and embryogenesis. For experimental embryos, I discarded 
embryos that retained blood cells in circulation, or had blood cells that did enter 
circulation, but pooled in the vessels. However, I did use experimental embryos that 
exhibited no blood cells in circulation, no remodeling of the yolk sac vessels, continued 
cardiac contractility, and similar somitogenesis.    
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Control and experimental embryos (in the yolk sac with the ectoplacental cone 
punctured) were then fixed in 4% paraformaldehyde (Fisher Scientific, CAS No. 30525-
89-4) for one hour. After fixing, the PFA was removed and the embryos were washed 
three times in fresh 1x PBS, then stored in 1% sodium azide (Fisher Scientific, CAS NO. 
26628-22-8) 
The embryos were blocked with 200 µl of serum blocking buffer (SBT, 1x PBS, 
2% normal donkey serum [Sigma-Aldrich, Cat. D9663-10ML], 0.8% Triton X [Fisher 
Scientific, CAS No. 9002-93-1]) for 1 hour and then stained with 1:250 anti-α-actin 
smooth muscle Cy3 (Sigma-Aldrich, Cat. C6198-.2ML) in SBT, which is transiently 
expressed in the heart at this stage. They were then washed with 1x PBT (0.8% Triton) 
and then stored in 1% sodium azide at 4 °C until somite counting. The yolk sacs and 
amnion were removed from the embryos for somite staging before processing for optical 
projection tomography.   
After staining, the embryos were prepared for imaging with OPT. First, they were 
embedded in 1% agarose in 1x phosphate buffer solution (PBS). This was done by 
immersing the embryos in the agarose solution and aspirating it into a cut off pipette tip. 
While cooling, the pipette was manually rotated to center the embryo in the agarose. 
Once completely cooled, the agarose was removed and the section containing the embryo 
was cut away and placed in a dehydrating solution of 25% methanol (Fisher Scientific, 
CAS 67-56-1) in 1x PBS in a 15 ml centrifuge tube (MidSci, Cat. C50R). Complete 
dehydration of the embryos was accomplished by replacing the solution every 24 hours 
with 50%, 75%, 100%, and 100% methanol in 1x PBS solutions. Next, the embryos and 
agar were cleared with a 1:2 solution of Benzyl Alcohol (Fisher Scientific, A396-500) in 
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Benzyl Benzoate (Acros Organics, CAS 120-51-4) (BABB). After clearing overnight, the 
BABB wash was replaced with fresh BABB for storage and imaging.   
Imaging samples with OPT. Samples were imaged on a custom-made optical 
projection tomography (OPT) microscopy system at Baylor College of Medicine courtesy 
of Dr. Mary Dickinson’s lab. The OPT is made up of an excitation light source (with a 
531 nm filter for our purposes), a magnetic and motile sample stage, an emission filter of 
593 nm, and a camera (Fig. 2). The embryo mounted to a rotating metal chuck (that is 
magnetized to the rotating stage) suspended in a basin of BABB. A 2D image of the 
emitted light was collected every 0.3 degrees the embryo was rotated.   
Images collected from the OPT were aligned using NRecon to construct a 3D 
image of the heart. These files were then compatible with Imaris, a software program I 
used for data collection.  
 
Data collection 
To minimize the effects of age difference on the statistical analysis embryo hearts, 
the embryos were grouped in ranges of 3 somite pairs: <14, 14-16, 17-19, 20-22, and 23-
25. Unfortunately, enough samples were generated for only the 14-16 and 17-19 somite 
ranges. (Table 1). 
To assess the size of mouse embryo hearts, we looked at the volume contained by 
the myocardium. These measurements were obtained by outlining the inside of the 
myocardium throughout the 3D heart, including the trabecula (Fig. 3). The volume 
contained by the selection was calculated by Imaris and recorded.   
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The myocardial thickness was assessed by taking four measurements of the 
myocardium excluding the trabecula (Fig. 4) on five sections along the heart: one near 
the inflow tract, one near the outflow tract, and the other three were evenly spaced 
between the sections near the inflow and ouflow tracts.  
Statistical tests were performed using the two sample t-test in R, with a 
significance level of P <0.05. The number of samples produced for each condition (n) are 
listed in Table 1.  
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RESULTS 
 
After culturing the AT (Acrylamide and TEMED-injected) embryos for 24 hours, 
visual inspection of the AT embryos revealed the presence of heart contractions; however 
an absence of blood cells entering in circulation. This resulted in a lack of vascular 
remodeling of the yolk sac due to the reduction in hemodynamic force. Whereas, the N 
and Ao embryos did exhibit heart contractions, blood flow, and normal vascular 
remodeling—indicating that hemodynamic force is very high in these embryos. Embryos 
that were collected at E8.5, before they were manipulated, generally ranged from 4-6 
somites (before blood cells enter circulation). After approximately 24 hours of culturing, 
there was some variability in the stage of development that has been attained.  Mostly, 
the 14-16 somite or 17-19 somite groups had a sufficient amount of embryos for 
statistical analysis across all treatment groups (Table 1).  
Past studies have indirectly assessed stroke volume (Broekhuizen et al., 1999) and 
ejection volume (Hove et al., 2003) of the heart. Broekhuizen et al., 1999 found that there 
may be a compensatory mechanism increasing stroke volume in stage 34 chick embryos 
with ligation of the right lateral vitelline vein. The ejection volume in Hove et al., 2003 
was calculated to determine that the shear forces acting on the cardiac endothelial cells 
were significant. These studies approximate the volume of blood the heart expels. 
Unfortunately, such approximations cannot be obtained for the study as processing for 
OPT necessitates fixation of the embryos. However, the high resolution of the OPT does 
allow for direct measurements for the morphological volume. As such, direct 
measurements of the heart volume were successfully obtained using Imaris (as described 
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in Methods). Qualitative comparison of 3D images of the hearts between the AT (reduced 
hemodynamic loading) and the control embryos (N and AO) showed a lot of variability in 
sizes, even between embryos of the same somite stage group. So, statistical evaluation 
was needed to determine if there was a difference. Statistical analysis of the embryonic 
heart volumes revealed that there was no significant difference in the heart volumes 
between the AT (reduced hemodynamic loading) embryos and the control embryos (N 
and Ao) (Fig. 5; Fig. 6).  
Although there was no observable change in the heart volume when 
hemodynamic forces are reduced, measurements for volume were taken of the lumen of 
the heart itself (i.e., it did not include the myocardium). Thus, there could still be a 
change in thickness in the myocardium that I would not have been able to detect when I 
assessed heart volumes. It is possible that the thickness of the myocardium could be 
influenced during our culturing period because cardiomyocytes do proliferate between 
E8.5 and E9.5 (Zhao and Rivkees, 2003). Myocardial thickness was measured at multiple 
locations of the myocardium along the heart tube as described in methods. Statistical tests 
revealed a significant decrease in the myocardial thickness in AT embryonic hearts as 
compared to both of the controls at the 14-16 and 17-19 somite stages (Fig. 7; Fig. 8).  
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DISCUSSION 
 
Summary 
Considering that reduction of hemodynamic force (or hemodynamic loading in 
the heart) in reduced-hematocrit mouse embryos has been show to prevent blood vessels 
from properly remodeling, I expected that this could also impact development of the 
heart. This was further corroborated by other studies in zebrafish and chicken embryos 
where alterations in hemodynamic loading do result in a change in heart morphology 
(deAlmeida et al., 2007; Hove et al., 2003; Sedmera et al., 1999). When using OPT 
imaging to obtain high resolution 3D images of the mouse embryonic hearts, and by 
performing morphometric analysis, I were able to observe a small, but significant 
difference in myocardial thickness between low-hemodynamic loading embryos and 
controls, with no significant difference in total heart volume detected. 
The slight decrease in myocardial thickness observed in the low hemodynamic 
force embryos compared to embryos with normal hemodynamic force is in line with 
other studies showing stunted cardiovascular development with reduced blood forces 
(Anderson et al., 2015; Granados-Riveron and Brook, 2012; Hove et al., 2003; Lucitti et 
al., 2007; Sedmera et al., 1999). The reason for this may be that force sensing factors in 
the heart that signal cardiomyocyte proliferation are not being turned on. Notch signals 
are known to induce development of the vasculature in a hemodynamic force-dependent 
manner (Anderson et al., 2015). It is possible these or similar signals also play a role in 
the development of the heart itself.  
 27 
There are a couple of possible explanations for the lack of change in the heart 
volume: First, reduced hemodynamic loading does not affect heart volume (E8.5 to E9.5), 
and second the statistical power was not high enough to show a difference. The second 
explanation suggests that there could be a difference that is not detectable because our n-
value is too low. The reason for the low n-value was due to a combination of factors. 
First, litter sizes vary and some mice do not produce enough embryos. Second, the 
experiments depend on success of the dissections, injections, and culture. Performing 
these delicate procedures have a very long learning curve. Third, it is possible there is a 
developmental delay in the AT embryos that will be discussed later. These aspects of this 
project resulted in a long process of producing embryos for this experiment, leading to 
the low n-value. However, even with the low n-value, the number of embryos used for 
this study was very close to comparable studies (Anderson et al., 2015). Therefore, it is 
highly doubtful that adding more embryos to the study will reveal a significant difference 
in volume since there was so much variability seen from embryo to embryo (even within 
the same somite group). 
In conclusion, there was no observable difference in heart volume of mice 
cultured from E8.5 to E9.5 with reduced hemodynamic force compared to normal mice 
with normal hemodynamic force. A slight decrease was observed in the myocardial 
thickness between mice with reduced hemodynamic force and the control mice. It is 
possible that decreased homodynamic force has other implications in heart development. 
There are other aspects of heart development that can be assessed with this data set, but 
are not included in this study due to time constraints.   
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Future Direction  
One aspect of heart development that was not assessed in this study is the role 
lowered hemodynamic force plays in the development of trabecula. Trabecualtion does 
not occur in zebrafish when there are mutations in genes that decrease blood flow in the 
ventricles (Haack and Abdelilah-Seyfried, 2016). Trabecula were observed in the hearts 
generated for this study (Fig. 3A). Therefore, an assessment of their development is 
warrented.  
Another event in heart development that can be investigated with this data set is to 
determine if low hemodynamic force impacts looping. Mice with mutations in DLL4, 
which plays a role in vascular development) have less looping of the heart tube 
(Anderson et al., 2015). As such, the extent of looping in the low hemodynamic force 
embryos vs. the control embryos needs to be determined.  
Since there seemed to be a delay in the somitogenesis of the AT embryos 
compared to the controls, as there was a singular embryo produced that was more than 19 
somites in the AT group, one thing that can be assessed is whether or not mutations that 
reduce hemodynamic force are also delayed. This may be corroborated by assessing 
somitogenesis in Myl7 mutant strain, which presents decreased homodynamic force due 
to decreased contractility in the atria that effects heart development (Anderson et al., 
2015; Culver and Dickinson, 2010; Lucitti et al., 2007).  
This study looked at embryos in static culture from E8.5 until E9.5. In Lucetti et 
al. 2007, they used roller culture. This helps circulate the nutrients and wastes in the 
medium and allows for more robust growth of the embryo vs. static culture. Other studies 
have cultured embryos from a more advanced age (E11) and longer (36 hours) (Yashiro 
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et al., 2007). If embryos at E11 and beyond are to be assessed, alternative mechanical 
manipulations of hemodynamic force may need to be explored as hematopoiesis begins in 
the liver at that stage (Conrad et al., 2004).  
One study observed that ligating the left sixth brachial arch artery (BAA) on the 
BAA and the dorsal aorta at E11.5 lead to regression of the left BAA (Yashiro et al., 
2007). While this study did not assess heart development, it is possible that an atrial 
ligation similar to that in chick embryos (Hove et al., 2003) at this E11.5 stage may 
provide insight on hemodynamic forces in heart development. In the study by Yashiro et 
al., 2007, they also looked at how propranolol (a β-adrenergic antagonist that decreases 
heart rate) effected the development of the BAA. Treating embryos with this or other 
drugs that influence heart rate are also possible ways to see if hemodynamic forces are 
important for heart development.  
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Table 1. Number of embryos in somite groups per treatment (N= no injection, Ao= 
acrylamide only, AT= acrylamide and TEMED). . 
 
 Treatment 
Somite Group N Ao AT 
<14 0 0 7 
 
14-16 3 7 12 
 
17-19 5 7 7 
 
20-22 4 6 1 
 
23-25 0 5 0 
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Figure 1. Experimental set up. All embryos were collected at E8.5 and consisted of the 
following groups: controls with no injections (N embryos) (A.), controls with only 
acrylamide injected into the blood islands (Ao embryos) (B.), and experimental embryos 
with both acrylamide and TEMED injected into the blood islands (AT embryos) (C.).  
Figure 2. OPT set up. The OPT microscopy system consists of and excitation light source 
(as well as a white light source for autoflourescence), the specimen chamber with BABB, 
a motile and magnetic stage with a metal chuck with the specimen attached, and a camera 
to collect images directly onto a computer.  
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Figure 3. Volume data collection. Imaris was used to assess the volume of the hearts. 
This was accomplished by outlining the inner myocardium in multiple sections 10 um 
apart (A. & B.), and then combining these selections to create a volume (C.) that is then 
calculated by Imaris. (T=trabecula). 
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Figure 4. Myocardial thickness data collection. The myocardial thickness was 
measured in four places on five sections between the inflow to the outflow tracts. 
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Figure 6. Decreased hemodynamic loading does not impact heart volume. Statistical 
analysis of heart volume at the 14-16 (A.) and 17-19 (B.) somite stages did not reveal a 
significant difference between the controls themselves (N to Ao), nor between the 
controls compared to the controls and experimental hearts (N to AT and Ao to AT 
p>0.05).  
 
Figure 5. Representative images of volumes. Images of volumes used for the 14-16 
somite range (N=A., Ao=B., AT=C.) and the 17-19 somite range (N=D., Ao=E., AT=F.). 
Scale bar 100 µm.   
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Figure 8. Myocardial thickness slightly decreases under low hemodynamic loading. 
Statistical analysis showed no difference in myocardial thickness at 14-16 (A.) and 17-19 
(B.) somite stages between the controls (N and Ao). However, both somite stages showed 
a decrease in the myocardial thickness of AT embryos compares to the controls (N to AT 
and Ao to AT p<0.05).  
 
Figure 7. Representative images of myocardial thickness. Images of myocardial slices 
used for the 14-16 somite range (N=A., Ao=B., AT=C.) and the 17-19 somite range 
(N=D., Ao=E., AT=F.). Scale bar 100 µm.  
 
